Recently Featured

Small Drugmakers Negotiate Pricing Deals with White House Amid Tariff Threats

April 14, 2026
WASHINGTON — The Trump administration is actively negotiating new drug-pricing agreements with smaller pharmaceutical companies, as reported by multiple sources familiar with the discussions, including a White House official. This initiative provides an avenue for smaller firms—previously excluded from earlier negotiations—to commit to lower pricing structures, potentially shielding themselves from impending tariffs and new Medicare…

UK Signs Off on US Pharma Deal, Ensuring Tariff Reprieve as Britain Aims to Reattract Investments

April 13, 2026
The U.K. government has officially signed a deal with the United States that eliminates tariffs on pharmaceuticals, a strategic move aimed at revitalizing investment in the British healthcare sector. This agreement not only facilitates smoother trade relations but also positions the U.K. as an attractive destination for pharmaceutical companies seeking to expand their operations in…

BioNTech to Close Singapore Vaccine Facility as Demand Shifts Post-Pandemic

April 13, 2026
BioNTech is set to close its Singapore vaccine manufacturing facility, which was acquired from Novartis during the COVID-19 pandemic, signaling a significant shift in the company’s operational strategy as global demand for mRNA vaccines declines. This decision comes as the company seeks to align its production capacity with the current market realities, which have changed…

HNSCC Market Projected to Reach $4.5 Billion Across 8MM by 2034

April 13, 2026
GlobalData anticipates that the head and neck squamous cell carcinoma (HNSCC) market will reach $4.5 billion across eight major markets (8MM) by 2034, growing at a compound annual growth rate (CAGR) of 8.4%. This significant growth reflects the increasing prevalence of HNSCC and the ongoing advancements in treatment options, including immunotherapies and targeted therapies that…

Ongoing Cases